Understanding of known drug‐target interactions in the catalytic pocket of neuraminidase subtype N1
暂无分享,去创建一个
Thanyada Rungrotmongkol | Supot Hannongbua | Maturos Malaisree | Panita Decha | Ornjira Aruksakunwong | Pathumwadee Intharathep | T. Rungrotmongkol | S. Hannongbua | M. Malaisree | P. Decha | Pathumwadee Intharathep | Ornjira Aruksakunwong
[1] J. McKimm-Breschkin,et al. Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.
[2] D. Baker,et al. Molecular dynamics in the endgame of protein structure prediction. , 2001, Journal of molecular biology.
[3] T. Hien,et al. Avian influenza A (H5N1) , 2005, Journal of Clinical Virology.
[4] G. Air,et al. A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase , 1995, Proteins.
[5] Larisa V. Gubareva,et al. Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.
[6] P. Colman,et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.
[7] E. De Clercq,et al. Antiviral agents active against influenza A viruses , 2006, Nature reviews. Drug discovery.
[8] P. Kollman,et al. A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .
[9] Irwin D Kuntz,et al. Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations. , 2003, Journal of medicinal chemistry.
[10] H. Berendsen,et al. Molecular dynamics with coupling to an external bath , 1984 .
[11] Barry Honig,et al. Extending the Applicability of the Nonlinear Poisson−Boltzmann Equation: Multiple Dielectric Constants and Multivalent Ions† , 2001 .
[12] A. Moscona,et al. Oseltamivir resistance--disabling our influenza defenses. , 2005, The New England journal of medicine.
[13] Pooran Chand,et al. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. , 2005, Bioorganic & medicinal chemistry.
[14] Julie Dawn Thompson,et al. Improved sensitivity of profile searches through the use of sequence weights and gap excision , 1994, Comput. Appl. Biosci..
[15] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[16] T. Darden,et al. The effect of long‐range electrostatic interactions in simulations of macromolecular crystals: A comparison of the Ewald and truncated list methods , 1993 .
[17] R. Webster,et al. H5N1 influenza--continuing evolution and spread. , 2006, The New England journal of medicine.
[18] R. Webster,et al. Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses , 2001, Antimicrobial Agents and Chemotherapy.
[19] K. Sharp,et al. Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .
[20] G. Ciccotti,et al. Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .
[21] P. Colman,et al. Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.
[22] Pooran Chand,et al. Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase. , 2005, Bioorganic & medicinal chemistry.
[23] Vasiliy P. Mishin,et al. Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.
[24] J. Montgomery,et al. Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir , 2001, Antimicrobial Agents and Chemotherapy.
[25] A. Velázquez‐Campoy,et al. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. , 2000, Biochemistry.
[26] P. Kollman,et al. Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation , 1993 .
[27] J. McKimm-Breschkin. Neuraminidase inhibitors for the treatment and prevention of influenza , 2002, Expert opinion on pharmacotherapy.
[28] G. Boivin,et al. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. , 2007, Antiviral research.
[29] Supot Hannongbua,et al. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. , 2007, Biophysical journal.
[30] Pascal Bonnet,et al. Molecular dynamics and free energy analysis of neuraminidase–ligand interactions , 2004, Protein science : a publication of the Protein Society.
[31] I. Barr,et al. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. , 2007, Antiviral research.
[32] F. Hayden,et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.
[33] Guy Boivin,et al. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. , 2002, Antiviral research.
[34] M R Lee,et al. Use of MM‐PB/SA in estimating the free energies of proteins: Application to native, intermediates, and unfolded villin headpiece , 2000, Proteins.
[35] Erik De Clercq,et al. Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.
[36] S. Bantia,et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. , 2006, Antiviral research.
[37] A J Elliott,et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.
[38] G. Drusano,et al. Phenotypic Drug Susceptibility Assay for Influenza Virus Neuraminidase Inhibitors , 2004, Clinical Diagnostic Laboratory Immunology.
[39] David J. Stevens,et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.